Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients

by Thomas Christensen, Tobias Berg, Lise Birk Nielsen, Michael Andersson, Maj-Britt Jensen, Ann Knoop
Published 2020-06-01

Cardiotoxicity of Pertuzumab Containing Regimens for HER-2 Positive Breast Cancer

by Lin, Michelle, Wong, Nicolas
Published 2017

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer

by Michela Donadio
Published 2018-06-01

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

by Jagosky M, Tan AR
Published 2021-06-01

HER2‐positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab‐based chemotherapy: A case report

by Raffaele Longo, Pierre‐Olivier Legros, Marouane Talbi, Marc Wagner, Elena‐Adinisia Paraschiv, Marco Campitiello, Francesca Plastino, Antonio Rozzi
Published 2020-12-01

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer

by Sameer Batoo, Soley Bayraktar, Eyad Al-Hattab, Sandeep Basu, Scott Okuno, Stefan Glück
Published 2019-01-01

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab

by Jie Li, Maoguang Ma, Xuesong Yang, Maolei Zhang, Jingyan Luo, Huangkai Zhou, Nunu Huang, Feizhe Xiao, Bingquan Lai, Weiming Lv, Nu Zhang
Published 2020-09-01

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER

by O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya
Published 2021-05-01

Long-term survival in a young woman with recurrent HER2-positive breast cancer.

by Gianluca Cotroneo
Published 2018-06-01

Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breas...

by Tobias Berg, Maj-Britt Jensen, Erik H. Jakobsen, Sami Al-Rawi, Julia Kenholm, Michael Andersson
Published 2020-12-01

Breast cancer: from guidelines to personalized oncology

by Conte PierFranco, Guarneri Valentina
Published 2013-06-01

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Stand...

by Tamara Díaz-Redondo, Tamara Díaz-Redondo, Rocio Lavado-Valenzuela, Rocio Lavado-Valenzuela, Begoña Jimenez, Begoña Jimenez, Tomas Pascual, Fernando Gálvez, Alejandro Falcón, Maria del Carmen Alamo, Cristina Morales, Marta Amerigo, Javier Pascual, Alfonso Sanchez-Muñoz, Alfonso Sanchez-Muñoz, Macarena González-Guerrero, Luis Vicioso, Luis Vicioso, Aurora Laborda, Maria Victoria Ortega, Maria Victoria Ortega, Lidia Perez, Lidia Perez, Aranzazu Fernandez-Martinez, Nuria Chic, Jose Manuel Jerez, Jose Manuel Jerez, Martina Alvarez, Martina Alvarez, Martina Alvarez, Aleix Prat, Nuria Ribelles, Nuria Ribelles, Emilio Alba, Emilio Alba, Emilio Alba
Published 2019-11-01

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab

by Zhang Y, Wu S, Zhuang X, Weng G, Fan J, Yang X, Xu Y, Pan L, Hou T, Zhou Z, Chen S
Published 2019-12-01

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

by Jung Won Shin, Soohyun Kim, Suji Ha, Byungsan Choi, Seongyeong Kim, Seock-Ah Im, Tae-Young Yoon, Junho Chung
Published 2019-10-01

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation

by Babak Nami, Hamid Maadi, Zhixiang Wang
Published 2019-03-01

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

by De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N
Published 2018-04-01

The Conundrum of Adjuvant HER2 Treatment Options

by Ajaz Bulbul, Ajaz Bulbul, Emilio Araujo-Mino, Emilio Araujo-Mino, Zoneddy Ruiz Dayao
Published 2018-05-01

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab

by Juliana Bentes Hughes, Marianne Skeie Rødland, Max Hasmann, Inger Helene Madshus, Espen Stang
Published 2012-06-01

Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer

by Amit Rauthan, Palanki Satya Dattatreya, Manish Singhal, Ram Prabu, Siddharth Naik, Anil Kukreja
Published 2015-07-01

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer

by Maria Moritti, Evaristo Maiello
Published 2018-06-01